You are here
Vertex Shareholders Approve Proxy Proposals at Annual Meeting
At the meeting, shareholders re-elected director nominees Matthew W.
"Ms. McGlynn will provide our Board with invaluable commercial expertise
as we await the approval of INCIVEK for people with hepatitis C," said
Also at today's Annual Meeting, Vertex shareholders voted in favor of
the compensation of Vertex's named executive officers and voted for the
next advisory vote on the company's executive compensation program to be
conducted next year. Shareholders also ratified the selection of
Vertex creates new possibilities in medicine. Our team aims to discover, develop and commercialize innovative therapies so people with serious diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, epilepsy and other life-threatening diseases.
Founded more than 20 years ago in
INCIVEKTM is a trademark of
News Provided by Acquire Media